Hydralazine Should NOT Be Used in Severe Pulmonary Hypertension
Hydralazine is contraindicated and potentially dangerous in patients with severe pulmonary hypertension and should be avoided. The FDA drug label explicitly warns that hydralazine "may increase pulmonary artery pressure in patients with mitral valvular disease" 1, and clinical evidence demonstrates serious adverse outcomes when used in pulmonary hypertension patients.
Why Hydralazine Is Harmful in Pulmonary Hypertension
Evidence of Harm
The most compelling evidence comes from a 1982 study that evaluated hydralazine in 13 consecutive patients with primary and secondary pulmonary hypertension 2. Despite reducing systemic vascular resistance by 40%, hydralazine:
- Produced only minimal decreases in pulmonary arteriolar resistance (21%)
- Failed to improve stroke volume or pulmonary artery pressure
- Caused marked systemic hypotension (mean arterial pressure fell 17.5 mmHg)
- Led to symptomatic hypotension in 4 patients within 24 hours
- Required pressor support in 2 patients
- Resulted in 1 death
- Caused progressive renal insufficiency in 1 patient
- Decreased systemic oxygen saturation in another patient
Mechanism of Harm
Hydralazine preferentially dilates systemic vessels over pulmonary vessels in severe pulmonary hypertension. This creates a dangerous mismatch:
- Systemic vascular resistance drops dramatically
- Pulmonary vascular resistance remains elevated
- Systemic blood pressure falls precipitously
- Right ventricular afterload is not adequately reduced
- Reflex tachycardia increases myocardial oxygen demand
- Cardiac output may actually decrease despite vasodilation
Current Guidelines Exclude Hydralazine from PAH Treatment
Established PAH-Specific Therapies
Modern guidelines from CHEST 3, 4, ESC/ERS 5, and other major societies recommend only the following drug classes for pulmonary arterial hypertension:
- Endothelin receptor antagonists (bosentan, ambrisentan, macitentan)
- Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)
- Prostacyclin pathway agonists (epoprostenol, treprostinil, iloprost, selexipag)
- Soluble guanylate cyclase stimulators (riociguat)
Hydralazine is conspicuously absent from all contemporary PAH treatment algorithms 3, 5, 4.
Historical Context
While early 1980s studies 6, 7, 8 showed hydralazine could reduce pulmonary vascular resistance in highly selected patients with:
- Pulmonary artery pressure <60 mmHg
- Pulmonary resistance <15 U/m²
- Pulmonary-to-systemic resistance ratio <0.7
These criteria exclude patients with severe pulmonary hypertension. Even in these selected patients, the response was unpredictable and potentially dangerous 2, 9.
The Only Appropriate Use: Heart Failure, NOT Pulmonary Hypertension
Hydralazine combined with nitrates has a role only in heart failure with reduced ejection fraction, not in pulmonary hypertension:
- For Black patients with NYHA class III-IV heart failure as add-on therapy 10, 11
- For patients who cannot tolerate ACE inhibitors or ARBs 10
- This indication is for left-sided heart failure, not pulmonary vascular disease
The 2024 ESC hypertension guidelines mention hydralazine only for acute severe hypertension in pregnancy (as a second-line IV option) or as a last-resort agent in resistant systemic hypertension 12—contexts completely different from pulmonary hypertension management.
Critical Monitoring Concerns
If hydralazine were ever considered (which it should not be in severe PAH), the FDA label requires 1:
- Complete blood counts and antinuclear antibody titers before and periodically during therapy
- Monitoring for lupus-like syndrome (high incidence with doses >200 mg/day)
- Assessment for peripheral neuritis
- Pyridoxine supplementation if neuropathy develops
- Caution in coronary artery disease (can precipitate myocardial ischemia)
What to Do Instead
For a patient with severe pulmonary hypertension:
- Confirm accurate diagnosis with right heart catheterization to distinguish PAH (Group 1) from other PH groups 3
- Refer to a pulmonary hypertension specialty center 13, 5
- Initiate PAH-specific therapy based on WHO functional class and risk stratification 5, 4:
- Endothelin receptor antagonists
- PDE-5 inhibitors
- Prostacyclin analogs
- Consider upfront combination therapy for high-risk patients
- Supportive measures: oxygen therapy, diuretics for volume overload, anticoagulation (controversial in PAH, individualized decision) 14, 5
- Evaluate for lung transplantation if refractory to medical therapy 15, 5
Common Pitfall to Avoid
Do not confuse pulmonary hypertension due to left heart disease (Group 2 PH) with pulmonary arterial hypertension (Group 1 PAH). Even in Group 2 PH, hydralazine is not indicated for the pulmonary hypertension itself—it may be used for systemic hypertension or heart failure, but this does not treat the pulmonary vascular component and may worsen hemodynamics 3.
Bottom line: Hydralazine has no role in treating severe pulmonary hypertension and carries significant risk of harm. Use evidence-based PAH-specific therapies instead.